![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) — In a launch issued beneath the headline “Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.” earlier at present by Myovant Sciences, Inc. (NYSE: MYOV), please observe that the date of the convention name was omitted from the headline. The corrected launch follows:
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022
Myovant Sciences (NYSE: MYOV), at present introduced it should host a webcast and convention name to debate company updates and monetary outcomes for its second fiscal quarter, ended September 30, 2022. The webcast and convention name will likely be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.
Investors and most of the people might entry the reside webcast right here. The reside webcast will also be accessed by visiting the corporate’s investor relations web page of Myovant’s web site at: https://investors.myovant.com/.
The webcast will likely be archived on the corporate web site for roughly one yr.
ABOUT MYOVANT SCIENCES
Myovant Sciences aspires to redefine care for girls and for males by purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed 5 profitable Phase 3 medical trials throughout oncology and ladies’s well being main to a few regulatory approvals by the U.S. Food and Drug Administration (FDA) for males with superior prostate most cancers, ladies with heavy menstrual bleeding related to uterine fibroids, and premenopausal ladies with reasonable to extreme ache related to endometriosis, respectively. Myovant additionally has obtained regulatory approvals by the European Commission (EC) and the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for girls with symptomatic uterine fibroids and for males with superior hormone-sensitive prostate most cancers. Myovant has a supplemental New Drug Application beneath assessment with the FDA for updates to the United States Prescribing Information (USPI) based mostly on security and efficacy information from the Phase 3 LIBERTY randomized withdrawal examine (RWS) of MYFEMBREE in premenopausal ladies with heavy menstrual bleeding attributable to uterine fibroids for as much as two years. Myovant is also conducting a Phase 3 examine to guage the prevention of being pregnant in ladies with uterine fibroids or endometriosis. In addition, Myovant is creating MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has accomplished a Phase 2a examine for feminine infertility as a part of assisted replica. Sumitovant Biopharma, Ltd., an entirely owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For extra info, please go to www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Investor Contact:
Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.
[email protected]
Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.
[email protected]
